🟢 80/100

This product is generally safe

  • Vitamin B3: 50mg is 1.4× the Tolerable Upper Intake Level (35mg)
  • 50% of ingredients have research evidence
C Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Vitamin B3: 50mg is 1.4× the Tolerable Upper Intake Level (35mg)

Label Data

4 Capsule(s) Serving Size
30 Servings
Other Combinations Product Type
50% Evidence Coverage

Supplement Facts — Evidence Check

50 mg (250% DV)
⚠️ Exceeds Tolerable Upper Intake Level by 1.4× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 50mg UL 35mg
N.O. Monster Proprietary Blend
3000 mg

Other Ingredients

Vegetable Gelatin Magnesium Stearate Silicon Dioxide FD&C Red #40

Label Claims — Verification

All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested use: As a dietary supplement, take 4 capsules with water. On gym days, take 30-60 minutes prior to workout. To avoid sleeplessness, do not take within 4 hours of bedtime.

Precautions: Use only as directed.

⚠️ Warnings & Precautions

If you are pregnant, nursing, have high blood pressure, heart or thyroid disease, diabetes, difficulty in urination due to prostate enlargement, taking a MAO inhibitor or any prescription drug, or have a serious medical condition, seek professional medical advice before taking this product.

Reduce or discontinue use if you experience nervousness, tremors, sleeplessness, nausea or loss of appetite.

Keep out of reach of children.

Do not use if safety seal is broken.

🧪 Formulation Notes

For adult use only.

Monster nitric oxide pumps Extreme muscle growth

Additional Information

Amazon X001SOVY49

Store in a cool dry location.

Made in USA

Product Details

UPC / SKU 6 89076 03915 4
DSLD Entry Date 2020-03-24
Product Type Other Combinations
Form Capsule
DSLD ID 214951
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →